Terms: = Skin cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
2156 results:
1. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon pd-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
2. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
[TBL] [Abstract] [Full Text] [Related]
3. Vaccimel immunization is associated with enhanced response to treatment with anti-pd-1 monoclonal antibodies in cutaneous melanoma patients - a case reports study.
Mordoh J; Schwab E; Bravo AI; Aris M; Barrio MM
Front Immunol; 2024; 15():1354710. PubMed ID: 38726010
[TBL] [Abstract] [Full Text] [Related]
4. Long-term survival after anti-pd-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
[TBL] [Abstract] [Full Text] [Related]
5. Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma skin cancers.
Ravipati A; Pradeep T; Nouri K
J Drugs Dermatol; 2024 May; 23(5):301-305. PubMed ID: 38709693
[TBL] [Abstract] [Full Text] [Related]
6. Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
Versluis JM; Blankenstein SA; Dimitriadis P; Wilmott JS; Elens R; Blokx WAM; van Houdt W; Menzies AM; Schrage YM; Wouters MWJM; Sanders J; Broeks A; Scolyer RA; Suijkerbuijk KPM; Long GV; Akkooi ACJV; Blank CU
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677880
[TBL] [Abstract] [Full Text] [Related]
7. Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma.
Qin L; Zhang G; Wu Y; Yang Y; Zou Z
Cancer Immunol Immunother; 2024 Apr; 73(6):103. PubMed ID: 38630135
[TBL] [Abstract] [Full Text] [Related]
8. Lifileucel: First Approval.
Keam SJ
Mol Diagn Ther; 2024 May; 28(3):339-344. PubMed ID: 38625642
[TBL] [Abstract] [Full Text] [Related]
9. Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Phoon YP; Lopes JE; Pfannenstiel LW; Marcela Diaz-Montero C; Tian YF; Ernstoff MS; Funchain P; Ko JS; Winquist R; Losey HC; Melenhorst JJ; Gastman BR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604813
[TBL] [Abstract] [Full Text] [Related]
10. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract] [Full Text] [Related]
11. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant pd-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
12. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
[TBL] [Abstract] [Full Text] [Related]
13. TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.
Wang L; Liu X; Han Y; Tsai HI; Dan Z; Yang P; Xu Z; Shu F; He C; Eriksson JE; Zhu H; Chen H; Cheng F
Cancer Lett; 2024 May; 590():216861. PubMed ID: 38583649
[TBL] [Abstract] [Full Text] [Related]
14. Deciphering and overcoming Anti-pd-1 resistance in Melanoma: A comprehensive review of Mechanisms, biomarker Developments, and therapeutic strategies.
Wang R; Chen Y; Xie Y; Ma X; Liu Y
Int Immunopharmacol; 2024 May; 132():111989. PubMed ID: 38583243
[TBL] [Abstract] [Full Text] [Related]
15. Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis.
Gudd CLC; Mitchell E; Atkinson SR; Mawhin MA; Turajlic S; Larkin J; Thursz MR; Goldin RD; Powell N; Antoniades CG; Woollard KJ; Possamai LA; Triantafyllou E
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580334
[TBL] [Abstract] [Full Text] [Related]
16. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology.
Lee CM; Wang M; Rajkumar A; Calabrese C; Calabrese L
Semin Arthritis Rheum; 2024 Jun; 66():152440. PubMed ID: 38579593
[TBL] [Abstract] [Full Text] [Related]
17. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract] [Full Text] [Related]
18. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
[TBL] [Abstract] [Full Text] [Related]
19. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-pd1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
Mangla A; Lee C; Mirsky MM; Wang M; Rothermel LD; Hoehn R; Bordeaux JS; Carrol BT; Theuner J; Li S; Fu P; Kirkwood JM
JAMA Oncol; 2024 May; 10(5):612-620. PubMed ID: 38546551
[TBL] [Abstract] [Full Text] [Related]
20. Assessing the use of anti-pd1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
Whitman ED; Totev TI; Jiang S; da Costa WL; Grebennik D; Wang H; Boca AE; Ayyagari R
BMC Cancer; 2024 Mar; 24(1):389. PubMed ID: 38539148
[TBL] [Abstract] [Full Text] [Related]
[Next]
